Latest Innovation News

Challenger Limited reported a robust 12% increase in normalized NPAT to $225 million for 1H25, underpinned by strong earnings, dividend growth, and strategic investments in technology and distribution channels.

Challenger Limited reported a robust first half of FY25, delivering a 12% rise in normalised net profit after tax and record annuity sales, underpinned by strategic technology investments and longer tenor products.

Infratil has increased its investment in CDC Data Centres by acquiring an additional 1.58% stake for approximately A$216 million, reinforcing its commitment to the fast-growing digital infrastructure sector.

Reliance Worldwide Corporation Limited reported a robust 14.8% revenue increase to US$676.5 million and a 31.8% rise in net profit after tax to US$67.2 million for H1 FY25, driven by the full contribution from its Holman Industries acquisition.

Simonds Group delivered a resilient $13.6 million EBITDA in 1H FY25 amid a soft residential market and announced a strategic acquisition of Dennis Family Homes to fuel future growth.

PYC Therapeutics is set to raise up to $146 million through a pro-rata entitlement offer, aiming to accelerate its RNA-based drug candidates targeting major unmet medical needs. Major shareholder support and underwriting commitments underpin the capital raise.

Memphasys has initiated clinical utility testing of its Felix™ System in Brazil through a partnership with Laboratorio Androscience, aiming to establish a foothold in the rapidly growing Latin American IVF sector.

Australian Bond Exchange Holdings has entered a strategic Liquidity Provision Agreement with ViewTrade Australia, aiming to broaden investor access to OTC securities globally through integrated technology and expanded market channels.

Green Critical Minerals has announced a major breakthrough with its VHD Graphite technology, delivering thermal diffusivity far surpassing copper and aluminium, promising a revolution in AI and high-performance electronics cooling.

Arizona Lithium has withdrawn its previous exploration plan for the Big Sandy Lithium Project, opting for a revised development approach with key stakeholder input, while accelerating construction at its Prairie Lithium Project in Canada.

Recce Pharmaceuticals reports strong Phase II results for its RECCE® 327 topical gel, achieving a 93% efficacy rate in treating serious skin infections and setting the stage for accelerated Phase 3 trials.

Smart Parking Limited has reported robust H1 FY25 results, underpinned by a strategic acquisition of Peak Parking LP and a fully underwritten $45 million equity raise to fund its US expansion.